ClinicalTrials.gg
RecruitingNCT06549660Updated Sep 4, 2024

PBMT in Providing Temporary Relief of Low Back Pain of Musculoskeletal Origin

An interventional study of Active PBMT and Placebo PBMT in Low Back Pain, sponsored by University of Nove de Julho. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Low Back Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Low Back Pain · Brazil.

Planned enrollment
59th of 122
68 · median 66
Started
2024
with 2 others
No phase
101 of 125
9 open now
Primary completion
2025-08
later than 5 of 11 live
Registered
119th of 125
by date
Lead sponsor
6 of 125
University of Nove de Julho

Among the 125 studies in Low Back Pain with a site in Brazil, this one is the 59th largest by planned enrollment of the 122 interventional ones that give a count, is one of 3 that started in 2024, is one of 101 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 119th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

10 of the 125 studies in Low Back Pain with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Low Back Pain with a site in Brazil, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effectiveness of PBMT for adjunctive use in providing temporary relief of minor chronic low back pain of musculoskeletal origin.

The main questions it aims to answer are:

(i) Is PBMT able to decrease pain intensity in patients with chronic low back pain of musculoskeletal origin? (ii) Is PBMT able to decrease disability in patients with chronic low back pain of musculoskeletal origin?

Researchers will compare active PBMT with placebo PBMT to see if active PBMT provides temporary relief of minor chronic low back pain of musculoskeletal origin.

Read the detailed description

To achieve the proposed objective it will be performed a randomized, triple-blinded (patients, therapists, and outcome assessors), placebo-controlled randomized study.

Sixty-eight patients will be randomly allocated to two treatment groups:

  1. Active treatment: Thirty-four patients will receive treatment with active PBMT.
  2. Placebo treatment: Thirty-four patients will receive treatment with placebo PBMT.

The treatment administration protocol will comprise: six sessions of treatment (with active or placebo PBMT, according to the previous randomization), two sessions a week, for three consecutive weeks, each procedure administration three to four days apart.

The data will be collected by a blinded assessor.

The study will comprise the following stages/phases:

  1. Pre procedure phase activities: (a) signing of informed consent form; (b) assignment of subject identification number; (c) randomization of subject to procedure group; (d) initial study qualification evaluation.
  2. Rescue pain management stabilization phase: (a) determination and recording of the individualized rescue pain management regimen; (b) VAS recording; (c) continued study eligibility evaluation.
  3. Pre-procedure administration phase activities: (a) pre-procedure variables recorded; (b) recording of pre-procedure measures.
  4. Procedure administration phase activities: (a) establishment of procedure administration visit schedule; (b) study procedure administration; (c) study procedure administration protocol; (d) procedure administration phase visits and evaluations.
  5. Post-procedure administration phase: one-month (30±4 days) period immediately following completion of the procedure administration phase.

The statistical analysis will follow the intention-to-treat principles as primary analysis, and per-protocol analysis will be secondary supportive analysis.

03

Conditions studied

  • Low Back Pain

Keywords

  • Photobiomodulation therapy
  • Pain intensity
  • Disability
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients seeking care for chronic low back pain, defined as having occurred and recurred over regular or irregular periods or intervals of time, persisting over at least the last 3 months;
  • Fluent in Portuguese;
  • Pain intensity (self reported) of at least 50 mm measured by a 0-100 VAS pain scale;
  • Pain of benign musculoskeletal origin wherein the etiology is tendinopathies, synovitis, bursitis, strain, and sprain, of traumatic or non-traumatic origin, as determined by the outcome assessor based on any one or combination of the following: (i) Prior diagnosis by a qualified licensed medical professional current within the last 2 years evidenced through source documentation; (ii) Previous records review, such as x-ray, MRI, CT scans, etc., where available, that indicate muscle or ligament injury and the absence of radiculopathies, fractures, tumors, and infectious diseases;
  • Patient willing and able to maintain the individualized pain regimen (it will be determined in the first phase of the study and it will comprise what the patient can use or cannot use to manage any low back pain that may arise throughout the course of study duration).

Exclusion criteria

Exclusion Criteria:

  • Pain intensity (self reported) of less than 50 mm measured by a 0-100 VAS scale;
  • Acute low back pain, defined as having persisted less than half the time over less than the last 3 months;
  • Pain is not episodic, such that it has either been continually present without respite over the past 3 months and/or there has not been recurrent episodes within the past 3 months;
  • Pain is of other than, or in addition to, benign musculoskeletal origin;
  • Prior surgical intervention to the intended treatment area that in the opinion of the outcome assessor may affect the study treatment and or outcomes assessment;
  • Neurologic deficit(s) that in the opinion of the outcome assessor may affect the study treatment and or outcomes assessment;
  • Peripheral nerve disease;
  • Secondary orthopedic problem(s) that in the opinion of the outcome assessor may affect the study treatment and or outcomes assessment;
  • Local and/or botulinum toxin (Botox®) injection for pain relief in or around the intended treatment area within 30 days prior to study enrollment;
  • Treatments such as chiropractic care, and acupuncture targeting the intended treatment area(s) within 30 days prior to study enrollment;
  • Current, active chronic pain disease, such as chronic fatigue syndrome, fibromyalgia, endometriosis, inflammatory bowel disease, interstitial cystitis diabetic neuropathic pain;
  • Current cancer or treatment for cancer in the past 6 months;
  • Significant heart conditions including chronic heart failure (CHF) and implantable heart devices such as a pacemaker;
  • Active infection, wound, or other external trauma to the areas to be treated with the PBMT;
  • Medical, physical, or other for, or sensitivity to, light therapy;
  • Pregnancy, breast feeding, or planning pregnancy prior to the end of study participation;
  • Female subject of childbearing age who is unwilling to engage in effective medical use while sexually active during the study procedure administration phase;
  • Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years;
  • Developmental disability or cognitive impairment that in the opinion of the outcome assessor would preclude adequate comprehension of the form and/or ability to record the study outcome assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Placebo comparator
    Placebo PBMT

    Placebo PBMT will be applied twice weekly (three to four days apart) for three consecutive weeks, resulting in six treatment sessions. The placebo treatment will be applied in three zones: a) inferior to transverse process at L3-L4 left; b) intervertebral spaces between L3-L4; and c) inferior to transverse process at L3-L4 right.

    Device: Placebo PBMT

  • Experimental
    Active PBMT

    Active PBMT will be applied twice weekly (three to four days apart) for three consecutive weeks, resulting in six treatment sessions. The active treatment will be applied in three zones: a) inferior to transverse process at L3-L4 left; b) intervertebral spaces between L3-L4; and c) inferior to transverse process at L3-L4 right.

    Device: Active PBMT

Interventions

  • DeviceActive PBMT

    Active with a dose of 165 J per site, resulting in a total dose of 495J.

  • DevicePlacebo PBMT

    Placebo, without therapeutic dose.

06

What researchers measure

Primary outcomes

  1. Proportion of individual subject successes

    Measured through degree of pain rating measured by an 0-100 mm (0-10 cm) Visual Analog Scale (VAS), that evaluates the degree of pain perceived by the patient on a scale ranging from 0 to 100, with 0 being 'no pain' and 10 'the worst pain imaginable'. Higher scores mean worse outcome.

    Time frame: 15 minutes after the final treatment (6th).

Secondary outcomes

  1. Degree of pain

    Degree of pain will be measured by an 0-100 mm (0-10 cm) Visual Analog Scale (VAS), that evaluates the degree of pain perceived by the patient on a scale ranging from 0 to 100, with 0 being 'no pain' and 10 'the worst pain imaginable'. Higher scores mean worse outcome.

    Time frame: 15 minutes after the final treatment (6th) and one month after the final treatment.

  2. Disability

    Disability will be measured by the 24-item Roland Morris Disability Questionnaire. The questionnaire consists of 24 items that patient has to answer 'yes' or 'no'. The minimum value is 0 and the maximum value is 24. Higher scores mean worse outcome.

    Time frame: 15 minutes after the final treatment (6th) and one month after the final treatment.

Other outcomes

  1. Subject Satisfaction with overall outcome rating

    Patient satisfaction will be measured by 5 point Likert Scale. The scale uses the following responses: very satisfied = 5; somewhat satisfied = 4; neither satisfied nor dissatisfied = 3; somewhat dissatisfied n=2; very dissatisfied =1. Highest scores indicates better satisfaction.

    Time frame: 15 minutes after the final treatment (6th) and one month after the final treatment.

  2. Perceived group assignment and rationale

    Perceived group assignment and rationale will be measured by the percentage of patients and outcome assessor who correctly perceived their procedure group assignment and the percentage of volunteers and outcome assessor who did not correctly perceive their procedure group.

    Time frame: 15 minutes after the final treatment (6th) and one month after the final treatment.

  3. Adverse events

    All adverse events that occur after randomization, including but not limiting, skin irritation, discoloration, rash, infection, increased pain or tenderness. The adverse events will be captured on the appropriate adverse event case report form.

    Time frame: 15 minutes after the final treatment (6th) and one month after the final treatment.

07

Study locations

1 of 1 sites recruiting
  • Laboratory of Phototherapy and Innovative Technologies in Health
    São Paulo, 01504-001, Brazil
    Recruiting
    • Ernesto Cesar Pinto Leal Junior, PhD · Contact+55 11 3385 9134
    • Ernesto Cesar Pinto Leal Junior, Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2025, 12 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 12 months is close to that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
Aug 20, 2024
Primary completionEst.
Aug 20, 2025
CompletionEst.
Oct 1, 2025
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06549660
Collaborators
Multi Radiance Medical
Responsible party
Ernesto Cesar Pinto Leal Junior (Full professor, University of Nove de Julho) — Principal investigator
First posted
Aug 12, 2024
Start date
Aug 20, 2024
Primary completion
Aug 20, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Sep 4, 2024

Study contacts

Ernesto Cesar Pinto Leal Junior, PhD
Contact
ernesto.leal.junior@gmail.com
+551133859134
Ernesto Cesar Pinto Leal Junior, PhD
principal investigator · University of Nove de Julho

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion